Platform overview
At Karalis-AI we deliver modular, in silico solutions designed to support pharmaceutical and biotech partners working on new antiinfectives—especially for Gram-negative targets.
EhpF protein (PDB ID: 3HGU)
Our technology blends mechanistic insight, AI-driven prediction, and experimental validation.
Mechanistic Screening & Prediction Tools
- Predict membrane permeability, intracellular accumulation, and antibacterial activity
- Model transporter-mediated entry via Trojan-horse compounds (e.g., enterobactin analogs, PfeA, TonB transporters)
- Explore siderophore recognition, uptake, and signaling pathways
Antimicrobial Peptide (AMP) Design
- Predictive evaluation of AMPs with enhanced intracellular delivery
- Structure-function modeling using MD and docking pipelines
- Biologically meaningful property prediction through custom-trained neural networks
AI-Driven Property Prediction
- Pretrained SMILES and NMR autoencoders adaptable to new datasets and compound libraries
- Support for high-throughput virtual screening
- Tailored AI models for partner-specific challenges, enabling applications outside of AMR
Integrated Experimental Validation
- Structure-based support via MD, docking, and NMR spectroscopy
- Optional collaboration for wet-lab validation and co-development projects
How we help
Precision tools for biotech and pharma — built for strategic investors
For Pharma and Biotech
- De-risk early discovery with mechanism-aware filters
- Reduce attrition with better hit selection
- Accelerate lead optimization with biology-grounded insights
- Extend AI models to peptides, small molecules, and conjugates
For Investors
- Positioned in the $50B+ AMR market with scalable computational tools
- Proprietary pretrained autoencoders ensure versatility across biotech domains
- Founded by scientists with a track record of translational research and innovation
Empower innovation in antimicrobial research
Let’s discuss how we can power your next discovery project